Review of gemcitabine-based combinations for platinum-resistant ovarian cancer

International Journal of Gynecological Cancer

Volumn 15, Issue SUPPL. 1, 2005, Pages 23-30

  Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chemotherapy; Combination; Gemcitabine; Ovarian cancer; Platinum resistant

Indexed keywords

DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; PLATINUM; TOPOTECAN; TREOSULFAN;

ANEMIA; BLOOD TOXICITY; CANCER RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACTIVITY; DRUG CHOICE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOXIA; INTERSTITIAL PNEUMONIA; LUNG TOXICITY; META ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL; RELAPSE; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 18844425731     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.15353.x     Document Type: Conference Paper

References (66)

1. Ferlay JF, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. IARC CancerBase No. 5. Lyon: IARCPress, 2001.
2. Berek JS, Bertelsen K, du Bois A et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10(Suppl.):87-92.
3. Lichtenegger W, Sehouli J, Buchmann E, Karajanev C, Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer. J Obstet Gynecol Res 1998;24:447-51.
4. McGuire PW, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
5. Du Bois A, Lueck HJ, Meier W. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial [abstract]. Proc Am Soc Clin Oncol 1999;18:356a. Abstract 1374.
6. McGuire PW, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340-8.
7. Ozols RF, Bundy BN, Fowler J. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) vs carboplatin (CARBO)/paclitaxel (PAC) in optimal stage III epithelial ovarian cancer (GOG 158) [abstract]. Proc Am Soc Clin Oncol 1999;18:356a. Abstract 1373.
8. Neijt JP. Ovarian cancer: rethinking prognostic factors and chemotherapy. ASCO (educational book). 1994;214-20.
9. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93.
10. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099-106.
11. Pfisterer J, Plante M, Vergote I et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract]. J Clin Oncol 2004;22(Suppl. 14S). Abstract 5005.
12. Conte PF, Gadducci A, Cianci C. Second-line treatment and consolidation therapies in advanced ovarian cancer. Int J Gynecol Cancer 2001;11(Suppl. 1):52-6.
13. Kavanaugh JJ, Kudelka AP, de Leon CG et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-42.
14. Hertel LW, Boder GB, Kroin JS et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990;50:4417-22.
15. Morant R Phase II study: gemcitabine in refractory metastatic prostatic carcinoma [abstract]. Proc Am Soc Clin Oncol 1997;16. Abstract 1109.
16. Lund B, Hensen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′2′-difluorodeooxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-3.
17. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
18. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol 1999;10:853-5.
19. Coenen M, Berteloot P, Amant F, Vangramberen M, Vergote I. Gemcitabine in platin-paclitaxel resistant ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 2000;19:28a. Abstract 1603.
20. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJM. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22(4 Suppl. 11):72-9.
21. Ruiz van Haperen VWT, Veerman G, Boven E et al. Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 1999;57:407-15.
22. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999;35:796-807.
23. Distefano M, Ferlini C, De Vincenzo R, Gaggini C, Mancuso S, Scambia G. Antagonistic effect of the combination of gemcitabine/topotecan in ovarian cancer cells. Oncol Res 2000;12:355-9.
24. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93.
25. Pectasides D, Papadopoulou M, Varthalitis J et al. Paclitaxel in cisplatin or carboplatin-pretreated ovarian cancer. Phase II study. Oncology 1998;55:228-34.
26. Trope C, Hogberg T, Kaern J et al. Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Ann Oncol 1998;9:1301-7.
27. Tay SK, Thilagam MD. Single agent paclitaxel in resistant and relapsed epithelial ovarian cancer after first-line platinum-based chemotherapy: experience in an Asian population. Ann Acad Med Singapore 1998;27:645-9.
28. Bolis G, Parazzini F, Scarfone G et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol 1999;72:60-4.
29. Andersson H, Boman K, Ridderheim M et al. An updated analysis of a randomized study of single agent paclitaxel (P) given weekly vs every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy [abstract]. Proc Am Soc Clin Oncol 2000;19. Abstract 380a.
30. Omura GA, Brady MF, Look KY et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 2003;21:2843-8.
31. Poole CJ, Perren T, Hogberg I et al. Phase I trial to investigate the optimal dose and schedule of gemcitabine and paclitaxel in combination in patients with previously treated epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1998;17:357a. Abstract 1380.
32. Roman L, Garcia AA, Facio G et al. Phase II study of weekly paclitaxel and gemcitabine in platinum resistant ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2001;20:220a. Abstract 877.
33. Jungnelius JU, Ridderheim M, Perren T, Gawande S, Roychowdhury D, Poole C. Optimal sequence leads to improved dose delivery for gemcitabine (G)/paclitaxel (P) combination in recurrent ovarian cancer: a phase I study [abstract]. Proc Am Soc Clin Oncol 2002;21:223a. Abstract 890.
34. Garcia AA, O'Meara A, Bahador A et al Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 2004;93:493-8.
35. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003;89(Suppl. 3):S9-15.
36. Trudeau MG, Fox SB, Samson B et al. Docetaxel and gemcitabine is an effective regimen in platinum-resistant ovarian cancer: a pilot study from the C.I.C.M. [abstract]. Proc Am Soc Clin Oncol 2003;22:485. Abstract 1951.
37. Kouroussis C, Mavroudis D, Kakolyris S et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 2004;44:363-8.
38. Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002;20:311-5.
39. Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudate of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
40. 2. Ann Oncol 2000;11:1029-33.
41. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22.
42. D'Agostino G, Ferrandina G, Ludovisi M et al. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer 2003;89:1180-4.
43. Tobias D, Runowicz C, Mandeli J et al. A Phase I trial of gemcitabine and Doxil for recurrent epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol 2000;19:392a. Abstract 1551.
44. Holloway RW, Finkler NJ, Nye LP, Bigsby GE, Ortiz B. Doxil and gemcitabine combination therapy for recurrent ovarian cancer: results of a phase II trial [abstract]. J Clin Oncol 2004;22(Suppl. 14). Abstract 5090.
45. Sehouli J, Oskay G, Katsares I et al. Biweekly schedule of pegylated liposomal doxorubicin (PLD) induces low rates of skin toxicities: results of a phase-II trial in heavily pre-treated patients with relapsed ovarian cancer [abstract]. J Clin Oncol 2004;22(Suppl. 14). Abstract 5072.
46. Hillcoat BL, Campbell JJ, Peperell R, Quinn MA, Bishop JF, Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985;22:162-6.
47. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12:60-3.
48. Markman M, Hakes T, Reichman B et al. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992;119:55-7.
49. Marzola M, Zucchetti M, Colombo N et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993;4:517-9.
50. Seymour, MT, Mansi C, Gallagher ME et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994;69:191-5.
51. Smyth RD, Pfeffer M, Scalzo A, Comis RL. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol 1985;12(1 Suppl. 2):48-51.
52. Lentz SE, Garcia AA, Bookman M et al. Phase I trial of gemcitabine and protracted etoposide in recurrent gynecological tumors: a Gynecologic Oncology Group study [abstract]. Proc Am Soc Clin Oncol 2000;19:405a. Abstract 1604.
53. Gore M, ten Bokkel Huinink W, Carmichael J et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 2001;19:1893-900.
54. Cole JL, Rinaldi DA, Lormand NA. Phase I trial of topotecan and gemcitabine for patients with previously treated, advanced non-small cell cancer [abstract]. Proc Am Soc Clin Oncol 1999;18. Abstract 1930.
55. Dabrow MB, Gilman PB, Meyer TJ. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic NSCLC [abstract]. Proc Am Soc Clin Oncol 1999;18. Abstract 500a.
56. Laufmann LR, Spiridonidis CH, Jones JJ. Gemcitabine and topotecan - a phase I trial [abstract]. ASCO 1999;18. Abstract 837.
57. Sun W, Stevenson JP, Gallagher M et al. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 2001;92:414-9.
58. Greggi S, Salerno MG, D'Agostino G et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 2001;60:19-23.
59. Sehouli J, Stengel D, Oskay G et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 2002;13:1749-55.
60. Sehouli J, Stengel D, Oskay G, Blohmer J, Kaubitzsch S, Lichtenegger W. Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie (NOGGO). Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum. Onkologie 2004;27:58-64.
61. Oskay-Özcelik G, Sehouli J, Sommer H et al. Randomized phase III trial: topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer [abstract]. J Clin Oncol 2004;22(Suppl. 14S). Abstract 5139.
62. Bajetta E, Di Leo A, Biganzoli L et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996;14:2546-51.
63. George MJ, Heron JF, Kerbrat P et al. Navelbine in advanced ovarian epithelial cancer: a study of the French Oncology Centers. Semin Oncol 1989;16(2 Suppl. 4):30-2.
64. Ferrero A, Logrippo V, Spanu PG et al. Phase II study of gemcitabine and vinorelbine in recurrent ovarian cancer [abstract]. Int J Gynecol Cancer 2004;14(Suppl. 1):69. Abstract 241.
65. Meier W, Dubois A, Kuhn W et al. Topotecan vs treosulfan in recurrent ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A prospective randomized phase III study [abstract]. Proc Am Soc Clin Oncol 2003;22:450. Abstract 1810.
66. Grecu OM, Kurbacher CM, Mallman P et al. Treosulfan and gemcitabine in heavily pretreated patients with breast and ovarian cancer: laboratory study and clinical pilot trial of the ISCO Clinical Study Group [abstract]. Proc Am Soc Clin Oncol 2001;20:187b. Abstract 2500.